936251-01-3

Usage

Uses

Used in Pharmaceutical Industry:
[(trans)-1-benzyl-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester is used as a key intermediate in the synthesis of potential pharmaceutical agents for the treatment of neurological and psychiatric disorders. Its unique chemical structure and pharmacological properties make it a promising candidate for further research and development in the field of medicinal chemistry.
Used in Medicinal Chemistry Research:
In the realm of medicinal chemistry research, [(trans)-1-benzyl-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester serves as a valuable compound for exploring new drug targets and mechanisms of action. Its specific structural features allow for the investigation of its interactions with various biological targets, potentially leading to the discovery of novel therapeutic approaches for neurological and psychiatric conditions.
Used in Drug Design and Synthesis:
[(trans)-1-benzyl-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester is utilized as a building block in the design and synthesis of new pharmaceutical agents. Its incorporation into drug candidates can potentially enhance their efficacy, selectivity, and pharmacokinetic properties, making it an important tool in the development of innovative treatments for neurological and psychiatric disorders.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 915100-73-1 (3R,4S)-1-benzyl-4-(2,4,5-trifluorophenyl)pyrrolidine-3-carboxylic acid 
• 75-65-0 tert-butyl alcohol 
• 936251-05-7 C₁₇H₁₅F₃N₂O₂ 
• 915100-66-2 (E)-1,2,4-trifluoro-5-(2-nitrovinyl)benzene 
• 165047-24-5 2,4,5-trifluorobenzaldehyde 
• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 
• 956924-25-7 2-nitro-1-(2,4,5-trifluorophenyl)ethanol 

Relevant academic research and scientific papers

1,4 DISUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS

Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR1 19. Compounds having stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.

CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS

Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR119. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention is directed to therapeutic compotmds of the following formula (I) which have activity as agonists of GPR 119 and are useful for the treatment of metabolic disorders including type II diabetes.

Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit

A novel series of pyrrolidine-constrained phenethylamines were developed as dipeptidyl peptidase IV (DPP4) inhibitors for the treatment of type 2 diabetes. The cyclohexene ring of lead-like screening hit 5 was replaced with a pyrrolidine to enable paralle

(3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: Synthesis, in vitro, in vivo, and X-ray crystallographic characterization

A series of pyrrolidine based inhibitors of dipeptidyl peptidase IV were developed from a high throughput screening hit for the treatment of type 2 diabetes. Potency, selectivity, and pharmacokinetic properties were optimized resulting in the identification of a pre-clinical candidate for further profiling.

Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)

The present invention relates to compounds, which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis, various immunomodulatory diseases, and other diseases.